Pharmacokinetic study

Comparative human
pharmacokinetics.

“Comparative human pharmacokinetic study of Berbisol™, Berbisol™ Plus and conventional berberine hydrochloride.”Under publication

Study design.

Design: Double-blind, balanced, randomised, single-dose, three-way crossover oral pharmacokinetic study
Participants: 30 adults
Intervention: 300 mg each of conventional berberine hydrochloride, Berbisol™ and Berbisol™ Plus
Measured: Free berberine concentration in the blood over 48 hours: peak concentration (Cmax) and total exposure (AUC)

Key outcomes.

Berbisol™Against conventional berberine hydrochloride extract

3×Higher Cmax: higher concentration in the blood

8×Higher AUC per mg: higher bioavailability

Berbisol™ PlusAgainst conventional berberine hydrochloride extract

2.7×Higher Cmax: higher concentration in the blood

7.8×Higher AUC per mg: higher bioavailability

The results.

Comparative pharmacokinetic profileFree berberine in the blood after a single 300 mg dose of each

Swipe the chart to see all 48 hours

Conventional berberine HClBerbisol™Berbisol™ Plus

The publication.

“Comparative human pharmacokinetic study of Berbisol™, Berbisol™ Plus and conventional berberine hydrochloride.” Under publication.

Full text available on request.

Request the full text About Berbisol™

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Next step

Working with ?

Tell us the format and the market, and we will send a sample with its specification.

Request a sample